Who
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
10% owner
Company insider
Files Form 4 as: 10% owner, ArriVent BioPharma; 10% owner, BeOne Medicines; 10% owner, Enfusion; 10% owner, Apellis Pharmaceuticals.
In numbers
- Trades disclosed
- 15
- Buys
- 2
- Sells
- 6
- Bought
- $20.0M
- Sold
- $4.2B
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 8 Feb 2016
- Last trade
- 10 Dec 2025
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Dec 2025filed 3 Feb 2026 | AVBP ArriVent BioPharmaBiotechnology | SEC FORM 4 Sold | $13.0M555,555 at $23.37 | filing |
| 2 Dec 2024filed 4 Dec 2024 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $3.6B17,842,500 at $200.00 | filing |
| 12 Jun 2023filed 12 Jun 2023 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $36.8M281,400 at $130.83 | filing |
| 12 Jun 2023filed 12 Jun 2023 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $207.2M968,812 at $213.91 | filing |
| 9 Jun 2023filed 12 Jun 2023 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $27.9M213,700 at $130.35 | filing |
| 9 Jun 2023filed 12 Jun 2023 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $71.4M328,952 at $217.02 | filing |
| 8 Jun 2023filed 12 Jun 2023 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $253.9M1,163,825 at $218.14 | filing |
| 25 Oct 2021filed 27 Oct 2021 | Enfusion | SEC FORM 4 Sold | $10.3M647,862 at $15.90 | filing |
| 13 Nov 2017filed 15 Nov 2017 | Apellis Pharmaceuticals | SEC FORM 4 Code C | —2,098,581 | filing |
| 13 Nov 2017filed 15 Nov 2017 | Apellis Pharmaceuticals | SEC FORM 4 Bought | $20.0M1,428,571 at $14.00 | filing |
| 13 Nov 2017filed 15 Nov 2017 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code C | —4,476,275 at $0.00 | filing |
| 8 Feb 2016filed 10 Feb 2016 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code C | —30,626,779 at $0.00 | filing |
| 8 Feb 2016filed 10 Feb 2016 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Bought | —9,100,000 | filing |
| 8 Feb 2016filed 10 Feb 2016 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code C | —14,814,814 at $0.00 | filing |
| 8 Feb 2016filed 10 Feb 2016 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code C | —15,811,965 at $0.00 | filing |
News
ArriVent BioPharma (AVBP) Securities Investigation NoticeAVBP · prnewswire.com · 13 Oct 2026Q3 EPS Estimate for ArriVent BioPharma Increased by AnalystAVBP · dailypolitical.com · 13 Oct 2026ArriVent BioPharma (NASDAQ:AVBP) Rating Lowered to Strong Sell at Wall Street ZenAVBP · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name HILLHOUSE INVESTMENT MANAGEMENT, LTD.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.